AFT Pharmaceuticals (NZE:AFT, ASX:AFP) reported a net loss after tax of NZ$2.4 million for the six months to September, compared with a net profit of NZ$1.8 million in the year-earlier period on the back of demand disruptions, according to a Thursday filing with the New Zealand and Australian bourses.
Operating revenue rose 4% to NZ$86.7 million, owing to double-digit sales growth in Australasia. Revenue in international and Asian markets fell due to reduced demand from key customers.
Fiscal 2025 operating profit is expected to range from NZ$15 million to NZ$20 million, which AFT Pharmaceuticals Chair David Flacks said is lower than the company's expectations at the start of the year.
AFT Pharmaceuticals' shares were up nearly 3% in recent Thursday trade in New Zealand.
Price (AUD): $2.61, Change: $+0.07, Percent Change: +2.76%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.